St. Jude Medical (St. Paul, Minnesota) reported the enrollment of the first patient in the EnligHTN III trial, a study evaluating the safety and performance of the new second-generation EnligHTN Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.

Two devices regulated as drugs in India are cardiac stents and drug eluting stents (DES). For years, the market has been dominated by international device manufacturers like Abbott (Abbott Park, Illinois), Boston Scientific (Natick, Massachusetts) and Medtronic (Minneapolis). These companies produce most of the 3 million stents used in India every year.